



2027 EDITION

INDUSTRY PARTNER CONSORTIUM

Membership Directory

Members at a glance

INDUSTRY PARTNERS

AbbVie **04**

AstraZeneca **07**

bioAffinity Technologies **10**

Booz Allen Hamilton **12**

Bristol Myers Squibb **14**

Cognition Therapeutics **18**

Eli Lilly and Company **20**

Genentech **22**

GenMab **26**

GSK **29**

J&J Innovative Medicine **33**

Pfizer **37**

Siemens Healthineers **40**

Smith+Nephew **41**

Takeda **43**

NPC REPRESENTATIVES

Brittany Baber, Executive Director **47**
Lowcountry Center for Veterans Research

Jean Fresier **48**
Name, Title

Caitlin Mahaney, Executive Director **49**
Name, Title

Newton Ong **50**
Name, Title

Chris Wood, Executive Director **51**
Dorn Research Institute

Industry Partners



AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas – immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.

Mark Edwards, PharmD

Principal National Medical Outcomes Science Liaison



Mark is a Principal National Medical Outcomes Science Liaison at AbbVie, supporting Government Accounts across VA and DOW. He partners with federal healthcare decision makers to communicate clinical and health economic evidence, improve appropriate medication access, and support patient-centered outcomes for Veterans, active-duty service members, and their families. He also serves as the lead MOSL for AbbVie Clinical Research efforts in the VA across the entire portfolio. Mark brings more than two decades of pharmacy, medical affairs, managed care, and long-term care experience, including prior roles as a Federal & Regional Medical Outcomes Science Liaison, Senior Medical Science Liaison in immunology/dermatology, consultant pharmacist, and pharmacy operations leader. He earned his Doctor of Pharmacy from Campbell University.

Rachael Lydon

Study Project Manager II



Rachael has more than fifteen years of experience in clinical research, spanning both sponsor and institutional settings. She has been with AbbVie for the past ten years and currently serves as a Study Project Manager within the Neuroscience Therapeutic Area. In this role, she has led complex studies evaluating novel therapies in Alzheimer's disease, and most recently, PTSD.

As a wife of a Marine Corp veteran, Rachael has a personal connection to the veteran community, making research that has the potential to improve the lives of veterans and their families especially meaningful to her.



AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines in Oncology, Rare Diseases, and Biopharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit www.astrazeneca-us.com and follow us on social media [@AstraZeneca](#).

Ric Nannini, PharmD, MBA

National Oncology Account Director – Veterans Affairs



Ric Nannini, PharmD, MBA serves as the National Oncology Account Director at AstraZeneca focusing on Veterans Affairs, supporting VA National and VISN level executives aligned with oncology care for Veterans.

Prior to AstraZeneca, Ric retired as a US Army, Colonel with over 24 years of continuous active-duty service in roles including pharmacy director, health system executive and deputy pharmacy consultant to the US Army Surgeon General at prominent institutions such as Walter Reed and the US Military Academy at West Point.

While transitioning from military medicine to industry, Ric served as a federal pharmacy consultant to VA community care, pharmacy

benefit manager and military medicine in areas of specialty pharmacy, biologics, and oncology to optimize clinical decision support, pharmacy benefit design, payer provider models, and integration into health information technologies.

With over 30 years of experience promoting the adoption and integration of evidence-based practices, interventions, and policies across Federal healthcare, Ric is excited to lead the development and implementation of AstraZeneca's oncology market access strategy to advance oncology care and access for veterans.

Terreia S. Jones, Pharm.D.

Medical Director, Oncology Scientific Partnerships



Terreia Sutton Jones, Pharm.D., is the Medical Director for Scientific Partnerships in Oncology at AstraZeneca, supporting Veterans Affairs Nationally. With over 20 years of experience spanning clinical oncology pharmacy, cancer research, and the biopharmaceutical industry, she brings a uniquely integrated perspective that bridges patient care and science. Dr. Jones completed a clinical pharmacy residency at the VA Medical Center in Memphis, followed by postdoctoral research in anticancer drug pharmacogenomics at St. Jude Children's Research Hospital and a sabbatical in glioma mouse modeling at Memorial Sloan Kettering Cancer Center.

Her career spans academic research leadership as a Clinical Assistant Professor at the University of Tennessee Health Science Center, direct patient care as a Clinical Oncology Pharmacy Specialist within the Veterans Administration, and progressive Medical Affairs roles with top biopharmaceutical companies. She brings deep expertise in oncology Medical Affairs to her current role. Dr. Jones is deeply passionate about ensuring that the men and women who have served our country have access to the highest quality oncology care, and this commitment remains a driving force in her work on behalf of the Veterans Affairs community.



Science Driven.
Human Focused.
Real-World Impact.



NASDAQ: BIAF

Innovative, noninvasive healthcare solutions that begin with the early detection of lung cancer, the world's #1 cancer killer

LEAD PRODUCT:

CyPath Lung

Actionable results for early lung cancer detection, pulmonary nodule management and cancer surveillance

bioAffinity Technologies, Inc. (NASDAQ: BIAF) develops noninvasive healthcare solutions for the early detection and monitoring of lung disease. The Company's first commercial product, CyPath® Lung, is a noninvasive test designed to improve the early detection of lung cancer in patients at high risk for the disease. CyPath Lung uses advanced flow cytometry and proprietary artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. In a published clinical trial of high-risk patients, CyPath Lung demonstrated 92% sensitivity, 87% specificity, 88% accuracy and 99% negative predictive value (NPV) in detecting lung cancer in patients at high risk for the disease who had small indeterminate lung nodules less than 20 millimeters.

Our Commitment to Veteran Health

At bioAffinity Technologies, we are committed to improving the health of Veterans by developing noninvasive technologies that can help detect lung cancer earlier. Veterans carry a disproportionate burden of lung cancer, and we believe they deserve innovative approaches that can make screening, follow-up and care more effective and less invasive. Our work includes expanding access to the test within the Veteran healthcare system and collaborating with organizations serving Veterans, including NAVREF. Through these efforts, we are working to improve cancer outcomes for Veterans by enabling earlier detection and treatment so that more Veterans live longer, healthier lives.

Maria Zannes, J.D.



President and CEO

Ms. Zannes brings more than 30 years of executive-level management experience dedicated to defining and advancing company goals and overcoming obstacles impeding corporate success. Prior to her position at bioAffinity Technologies, Ms. Zannes founded The Zannes Firm focusing on strategic solutions for private industry in the medical, environmental and energy fields.

In her current capacity as bioAffinity Technologies CEO and President, she has built a team of award-winning scientists and executives who are advancing breakthrough oncology-focused diagnostics and therapeutics.

Ms. Zannes was President of the Energy Recovery Council, the national trade group for the \$10 billion waste-to-energy industry, and General Manager of ECOS Corporation, a subsidiary of Burlington Environmental.

Ms. Zannes also served as a project manager at

Wheelabrator Technologies, Inc. where she led project teams that developed, negotiated and financed the company's renewable energy generation facilities.

Ms. Zannes began her career as a journalist, working for Voice of America and the Associated Press. Before entering the business world, she served as a legislative aide specializing in energy policy and law for Representative Charles Wilson (D-TX). She is licensed to practice law in New Mexico. She has been awarded Lifetime Achievement Awards by the American Society of Mechanical Engineers and the Earth Engineering Center Award from the WTE Council of Columbia University.

She is the co-founder of two engineering research centers at Columbia University. Ms. Zannes received her BA in Journalism from the University of New Mexico and her JD from the University of Puget Sound in Washington State.

About Booz Allen

Overview

Booz Allen accelerates client missions with transformational technologies, passionate talent, and a commitment to fulfill our purpose: Empower People to Change the World®.

(AS OF 3/31/24)

FIRST TO THE FUTURE FOR 110 YEARS

Trusted to transform missions with the power of tomorrow's technologies, Booz Allen Hamilton advances the nation's most critical civil, defense, and national security priorities. We lead, invest, and invent where it's needed most—at the forefront of complex missions, using innovation to define the future. We combine our in-depth expertise in AI and cybersecurity with leading-edge technology and engineering practices to deliver impactful solutions. Combining 110 years of strategic consulting expertise with the perspectives of diverse talent, we ensure results by integrating technology with an enduring focus on our clients. We're first to the future—moving missions forward to realize our purpose: **Empower People to Change the World®**.

CLIENTS AND INDUSTRIES

Our clients trust us to solve their toughest problems with speed and scale. And our single profit-and-loss structure gives us the agility to deliver what our clients need, when and where they need it.

Defense

- U.S. Air Force
- U.S. Army
- U.S. Marine Corps
- U.S. Navy
- U.S. Space Force
- Joint Staff and Combatant Commands
- Office of the Secretary of Defense
- Military health

Intelligence

- U.S. intelligence agencies
- Military intelligence agencies
- Civil**
- Health agencies
- Security, law enforcement, and justice agencies
- Finance and economic development agencies
- Energy, environment, transportation, and space agencies

Global/Commercial

- Financial services
- Healthcare and life sciences
- Energy
- Technology

Key Facts

FOUNDED

1914

HEADQUARTERS

McLean, Virginia, USA

NYSE TICKER

BAH

EMPLOYEES

34,200

FISCAL YEAR

April 1 – March 31


REVENUE (AS OF 3/31/24)

Approx. \$10.7 billion

WEBSITE

BoozAllen.com

Executive Leadership



Horacio D.
Rozanski

Chairman,
CEO, and
President



Kristine
Martin
Anderson

Chief
Operating
Officer



Matt
Calderone

Chief
Financial
Officer

Media and Industry Analyst Inquiries

Jessica Klenk, Media Relations; klenk_jessica@bah.com; 703-377-4296

Investor and Financial Analyst Inquiries

investor_relations@bah.com

Dave Prakash

Chief Medical Officer



Dave Prakash is a physician technologist and Clinical Technology Advisor at Booz Allen Hamilton, where he brings clinical expertise and strategic insight to the firm's healthcare technology and innovation efforts. A former U.S. Air Force pilot and flight surgeon, Dave draws on a distinctive background spanning clinical medicine, aviation, technology, and consulting to help advance innovative solutions to complex healthcare challenges. His work focuses on bridging the gap between emerging technologies and real-world clinical needs, with a particular interest in improving healthcare and research for veterans.



Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

At Bristol Myers Squibb, we believe in the power of science to address some of the most challenging diseases of our time. Our focus on these unmet needs comes during a remarkable time, when unprecedented scientific breakthroughs are advancing the treatment of disease as never before in human history.

We work every day to transform patients' lives through science. Each day, our employees around the world work together for patients – they are at the center of everything we do. They inspire us. They are the reason we come to work each day. We combine the agility of a biotech with the reach and resources of an established pharmaceutical company to create a global leading biopharma company powered by talented individuals who drive scientific innovation.

We are proud of the advancements we have made in oncology, hematology, immunology and cardiovascular disease, and we are dedicated to helping patients prevail over serious diseases through our diverse and promising pipeline and new scientific platforms.

We know that our responsibility goes beyond medicine. We promote health equity globally and strive to increase access to life-saving medicines for populations disproportionately affected by serious diseases and conditions.

Patrick Krug

Director, Government Programs (VA/DoD); Veterans Community Network (PBRG) Executive Leadership Member



With a distinguished military background, Pat served in the United States Army as a proud member of the 4th Infantry Division from 1991 to 1994.

Over the course of 32 years, Pat contributed significantly to AstraZeneca for 24 years and has held leadership positions at BMS for 8 years. His roles have included Sales leadership, Compliance, Global Population Health, and US Managed Markets.

In the area of veteran and military-related focus, Pat played a role in leading the BMS Veterans Community Network (VCN). Under his guidance, the VCN achieved a remarkable 400% increase in veteran hiring from 2021 to 2023 compared to previous years. The year 2023 brought recognition in the form of the Veterans in Business- Corporation of the Year award, a testament to his outstanding efforts in supplier diversity.

Acknowledgments for his commitment to veterans include securing the #1 ranking for Best for Vets in 2022 and attaining the 8th position in 2023. The year 2022 marked a significant milestone with the prestigious Secretary of Defense Employer Freedom Award from the Employer Support of Guard and Reserves (ESGR), highlighting his unwavering support for military personnel.

Beyond his corporate roles, Pat actively engages in health equity-focused efforts, contributing to the ASCO Annual Conquering Veteran Cancer Together initiative. His involvement extends to serving on the AMSUS Executive Advisory Board. Furthermore, he has fostered impactful partnerships with Fisher House and Disable American Veterans, serving as 2:1 Employee Giving Partners and exemplifying a commitment to giving back to those who have selflessly served our nation.

Anthony DeLeon, PharmD, MS

Director, US HEOR & Field Access Scientific Support



Anthony DeLeon is the Director of Health Economics and Outcomes Research at Bristol Myers Squibb, bringing a 14-year tenure and over 21 years of pharmaceutical industry experience to his role. Dr. DeLeon earned his Doctor of Pharmacy and a Master of Science in Mental Health Outcomes Research from the University of Texas at Austin and completed a residency in Psychiatric Pharmacy Practice at Austin State Hospital in Austin, Texas. His expertise spans collaborative research across the BMS portfolio in neuroscience, immunology, hematology/oncology, and cardiovascular disease, with published HEOR research across multiple therapeutic areas. He also provides scientific support to enhance patient access to BMS medications with national payer customers, including the U.S. Department of Veterans Affairs. Dr. DeLeon currently serves as the HEOR lead for the VA, with several active collaborative study initiatives underway and continues to work to increase the visibility and integration of the VA in both real-world data and clinical research initiatives within BMS.

Samuel Villa, MBA

Director, Government Programs/Accounts




Sam has 33 years of biotech and pharmaceutical experience across sales leadership, commercial managed markets, government affairs, and federal accounts. In his current role at Bristol Myers Squibb, he supports a broad government accounts portfolio focused on expanding access to medicines across the VA and DoD channels.

Sam's commitment to serving Veterans, Warfighters, Service Members, and their families has been a defining focus of his work for more than 20 years. During his 16 years at Sunovion, he initiated the Field Director of Federal Markets role in 2005 and later helped smaller organizations build and strengthen their federal markets channels.

He also contributes to veteran and military community initiatives through the BMS Veterans Community Network (VCN), serves on the AMSUS Executive Advisory Board, the AVAHO Industry Relations Council and supports ASCO's Annual Conquering Veteran Cancer Together initiative. Sam previously received the Patriotic Employer Award from the National Committee for Employer Support of the Guard and Reserve (ESGR), recognizing his steadfast support for military personnel.

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company with 20 years of mechanistic, translational, and clinical research across neurodegenerative diseases. We are building on breakthroughs in well-established biological pathways underlying neurodegeneration, to lead the charge in developing accessible, novel small-molecule therapies for age-related degenerative diseases that have historically received limited investment.

Zervimesine (CT1812), our investigational, first-in-class oral therapy, has a unique mechanism of action that displaces toxic protein oligomers from neuronal receptors. This approach to tackling neurodegeneration translates across indications in which toxic oligomers drive disease progression, offering potential treatment for dementia with Lewy bodies, Alzheimer's disease, and Parkinson's disease, among others.



PROGRAM	PHASE 1	PHASE 2	PHASE 3	STATUS
ALZHEIMER'S DISEASE				
MILD-TO-MODERATE	COG0201 – SHINE			TOPLINE MID-2024
EARLY-TO-MILD	COG0203- START			ACTIVELY RECRUITING
DEMENTIA WITH LEWY BODIES				
MILD-TO-MODERATE	COG1201 – SHIMMER			TOPLINE 2H 2024
DRY AMD				
GEOGRAPHIC ATROPHY	COG2201 – MAGNIFY			ACTIVELY RECRUITING

Foundation

Cognition was founded by scientists who identified compounds that rescue the function of neurons in an *in vitro* model of Alzheimer's disease. To date, Cognition has identified five structurally distinct series of compounds that we believe possess advantages for specific disease indications and patient populations. Our lead candidate, CT1812, was selected from this library.

Clinical Development Strategy

Cognition retains all worldwide rights to CT1812 for all indications. To date, CT1812 has been studied in more than 250 people with dementia as well as healthy controls. CT1812 has been generally well tolerated and has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of Alzheimer's disease.

Alzheimer's Disease

We have completed eight clinical trials of CT1812 that enrolled healthy volunteers or patients with Alzheimer's disease, and two studies are ongoing. The Phase 2 COG0201 "SHINE" study (NCT03507790) has completed enrollment of 153 adults with mild-to-moderate Alzheimer's disease. Topline data are anticipated in mid-2024. SHINE is funded in part by approximately \$30 million in grant awards by the National Institute of Aging (NIA), a division of the National Institutes of Health.

The COG0203 "START" study (NCT05531656) is currently recruiting ~ 540 adults with early Alzheimer's disease. Notably, the START study will enable people to enroll if they are on stable doses of lecanemab, the first fully approved disease-modifying monoclonal antibody for early Alzheimer's disease. START is funded in part by a grant of approximately \$81 million awarded by the NIA.

Dementia With Lewy Bodies (DLB)

Approximately 1.4 million people are currently living with DLB, making it the second most common cause of dementia.

CT1812 is being studied in the Phase 2 COG1201 "SHIMMER" study (NCT05225415), which is enrolling approximately 120 adults with mild-to-moderate DLB. Participants in SHIMMER are permitted to have Alzheimer's co-pathology. Topline results are anticipated in 2H 2024. SHIMMER is funded by a grant of approximately \$30 million awarded by the NIA.

Geographic Atrophy (GA)

Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in people over 50 years of age in the United States.

CT1812 is being studied in the Phase 2 COG2201 "MAGNIFY" study (NCT05893537), which is enrolling approximately 246 adults with dry AMD and measurable geographic atrophy. Geographic atrophy is a lesion on the macula results in a loss of central vision.



Founded in 2007
25 full-time employees



IPO October 2021
– Proceeds ~\$45.2 million
– Overallotment ~\$6.8 million



\$170M+ in NIH grants awarded
to support clinical programs



– Lisa Ricciardi, President and
– CEO John Doyle, CFO
– Anthony Caggiano, M.D., Ph.D.,
CMO and Head of R&D

Please note: CT1812 is an experimental candidate and has not been approved by the U.S. FDA or other regulatory agencies.

For more information, please visit our website at www.cogrx.com or email us at info@cogrx.com

Theresa R. Devins, DrPH, MS



Vice President, Clinical Operations

Theresa R Devins, DrPH, MS has over 25 years of clinical research experience, having conducted many global studies ranging from Phase 1 to Phase 4 across a variety of indications including complex neurological diseases. She has extensive expertise recruiting underrepresented populations in clinical trials through trusted external partnerships and innovative community and site engagement. At Cognition Therapeutics, Dr. Devins is responsible for the oversight of all current and planned clinical trials for lead candidate, zervimesine (CT1812). To date she has overseen the completion of enrollment and overall study conduct in the SHINE (COG0201) study in mild-to-moderate Alzheimer's disease, SHIMMER (COG1201) study in mild-to-moderate dementia with Lewy bodies, MAGNIFY (COG2201) study in geographic atrophy secondary to dry age-related macular degeneration and Phase 2 START (COG0203) study in early Alzheimer's Disease.

Theresa works tirelessly to expedite clinical trials to bring new drugs to patients and their families who are waiting desperately for novel treatment options. She works closely with her study sites to gain insights on their experiences and from their study participants.

Her personal goal is to ensure Cognition Therapeutics is the sponsor of choice by providing a high level of service and managing site issues promptly. She also works hard to build vendor and CRO relationships, as these partnerships are the key to successful programs.



Lilly is a global healthcare leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded in 1876 by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission. To learn more, visit [lilly.com](https://www.lilly.com).

Cecile González-Cerimele

Executive Director - Patient Engagement: Access and Retention – Regulatory, Policy and Engagement Strategy



Cecile González-Cerimele is the Executive Director of Community Engagement in the Patient Engagement organization at Eli Lilly and Company. Guided by a lifelong love of science and a commitment to inclusion, representation, and access, she has spent over three decades in the pharmaceutical industry, working across the full arc of drug development, from discovery research to late-phase clinical programs. She has led teams managing multi-million-dollar programs and supported the launch of new portfolio entrants, consistently navigating unplanned obstacles while keeping focus on delivering medicines to patients. As a patient advocate, Cecile draws on her own personal experiences to ensure the patient perspective remains central—from early planning through execution.

Cecile has held numerous board positions, including with OLA, an Eli Lilly & Company Employee Resource Group, where she has built national and local strategic Hispanic partnerships to identify, recruit, and cultivate a pipeline of Latino talent within the company. She is a frequent invited speaker, sharing her experiences and perspective as a professional Latina in the pharmaceutical industry. Cecile holds a Bachelor's degree in Chemistry from Indiana University and is currently pursuing a Master's in Bioethics.

GO BEYOND THE SCIENCE

THEIR FIGHT, OUR MISSION **Pioneering Together for a Cancer-Free Tomorrow**

Together, we boldly create a future where all patients, regardless of circumstances, can access medicines that are precisely right for them.



Patient-Centered Care

- ▶ **20% of rural residents live >60 miles from a medical oncologist**, creating a barrier to treatment¹
- ▶ **Self-care for cancer patients proves difficult**, particularly within safety-net environments, due to reduced health literacy and various other barriers²



Equitable Care

- ▶ Black women are **41% more likely to die** of breast cancer than white women³
- ▶ Only about **5% to 15% of US clinical trial participants are Black or Latino**, yet non-white people are predicted to make up the majority of the US population by the year 2045⁴⁻⁷



Precision Medicine

- ▶ **1 in 3** patients with advanced non-small cell lung cancer **did not receive next-generation sequencing (NGS) testing**⁸
- ▶ White patients with NSCLC **received timely NGS testing at higher rates (~8%)** compared to Black or Latinx patients^{9,10}



How might we boldly impact patient care together?

GO BOLDLY. GO BEYOND. GO TOGETHER.

Patient-Centered Care

We strive to do better for patients: better experience, better health, better value, and better access to care within their communities.

Featured Initiatives:



We are proud supporters of the **American Cancer Society**.^{*} The American Cancer Society provides patient navigation and support programs, including ACS CARES™ app, which gives patients and caregivers the power to navigate their cancer journey with confidence through quality curated information and one-on-one support.




Genentech partnered with researchers to develop and validate the **4R Oncology Tool (Right Information and Right Care for the Right Patient at the Right Time)**. This care sequencing tool empowers patients to co-create viable care plans with their healthcare team.

Equitable Care

Genentech envisions and is building toward a healthcare system that is diverse and inclusive, accountable, and trustworthy to patients.

Featured Initiatives:



Genentech launched the **Advancing Inclusive Research Site Alliance**, a first-of-its-kind coalition working to advance representation of diverse patient populations in clinical trials and establish industry-wide best practices.



Love Letters is a cancer screening awareness program focused on Black and Latina women, created “by the community, for the community” to reduce care inequities. Developed in collaboration with NYC-area health systems and community organizations, it’s been expanding across the country.

Precision Medicine

We are leading the way in precision medicine, helping ensure that the right patient gets the right treatment at the right time.

Featured Initiatives:



Biomarker testing has redefined the therapeutic landscape for some cancers. Explore our **biomarkertesting.com** site to find educational resources, guidelines, and related coverage information on biomarker testing for healthcare professionals.



Genentech forged a **first-of-its-kind collaboration with OneOncology**, with the goal to develop, test, and share solutions to both provide personalized cancer care in communities nationwide and reduce disparities in access to that care.



How might we boldly impact patient care together?

Reach out to discuss further, or learn more about our initiatives at **genentechoncology.com**

^{*}These programs, including the ACS CARES App, are independently administered by the American Cancer Society. Genentech does not control and is not responsible for the execution of the programs.

References: 1. Levit LA, et al. *JCO Oncol Pract.* 2020;16(7):422-430. doi: 10.1200/OP.20.00174 2. Trosman J, et al. *JCO Oncol Pract.* 2021;17(8):e1202-e1214. doi:10.1200/OP.21.00161 3. American Cancer Society. Cancer facts and figures for African American/Black people 2022-2024. Available at: <https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/cancer-facts-and-figures-for-african-americans/2022-2024-cff-aa.pdf> Accessed October 5, 2023. 4. Coakley M, et al. *J Womens Health (Larchmt).* 2012;21(7):713-716. doi:10.1089/jwh.2012.37332 5. Ma MA, et al. *Mayo Clin Proc.* 2021;96(1):264-266. doi:10.1016/j.mayocp.2020.10.027 6. Garrick O, et al. *Ethn Dis.* 2022;32(1):61-68. doi:10.18865/ed.32.1.61 7. Vespa A, et al. United States Census Bureau. Report number P25-1144. February 2020. Accessed September 7, 2023. 8. Schwartzberg L, et al. *Future Oncol.* 2023;19(20):1397-1414. doi:10.2217/fon-2022-1216 9. Vidal G, et al. Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting. Presented at: American Society of Clinical Oncology, June 2-6, 2023; Chicago, IL. Accessed September 8, 2023. <https://meetings.asco.org/abstracts-presentations/219916> 10. Vidal G, et al. Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting. Presented at: American Society of Clinical Oncology, June 2-6, 2023; Chicago, IL. Oral presentation.

Kimberly Binaso, PharmD., BCGP, FASCP, FASHP

Medical Affairs Executive Director National Accounts: Federal



Kimberly Binaso is currently the National Medical Affairs Executive Director (MED) for Federal Accounts, supporting VA and DoD. In this role she is responsible for providing cross portfolio medical affairs support inclusive of identifying national health equity, clinical trial, and real-world evidence research opportunities.

Kimberly has over 20+ years of clinical pharmacy executive experience focused on clinical leadership roles that specialized in post-acute care geriatrics.

Prior to joining Genentech, Kimberly was a National Account Director for Sunovion Pharmaceuticals, externally supporting national Skilled Nursing Facility chain customers while internally supporting new

product launches, portfolio lifecycle strategy, and commercial contracting workstreams. She also served as the Vice President of Clinical Services at Managed Health Care Associates Inc. (MHA), the largest post-acute care GPO, and was responsible for leading a team of clinical pharmacists that provided oversight for all clinical engagements and decision-making resources across Long-Term Care, Home Infusion, and Specialty Pharmacy members.

Kimberly is a board-certified geriatric pharmacist and a fellow of both the American Society of Consultant Pharmacists and the American Society of Health-System Pharmacists. She completed her B.S. pharmacy degree at Rutgers University and her PharmD. at the University of Florida. She is a Board-Certified Geriatric Pharmacist.

Patricia Mader, M.S

Executive Director, Evidence Generation



Patricia Mader, M.S. is a clinical development professional with over 25 years of Biotech and Pharmaceutical industry experience. She currently leads the Genentech US Medical Affairs Evidence Generation team for Oncology-Hematology where she oversees the Clinical Operations, Data Sciences and Statistics functions and is accountable for the delivery of the data/insight generation portfolio of clinical trials and exploratory data analysis research. She has been with

Genentech for over 13 years and has held positions throughout the organization including Early Development, Global Clinical Operations and Medical Affairs. Prior to Genentech, Patricia worked for Amgen, Wyeth and Chiron in various research and development roles and held a Temporary Faculty Appointment/Lecturer at San Francisco State University. She earned a B.S. in Biology from the University of Illinois and an M.S. in Clinical Science from San Francisco State University with a focus in Immunology.



Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit [Genmab.com](https://www.genmab.com) and follow us on [LinkedIn](#) and [X](#).

Savreet Bains Chawla, M.S.




Director, Center for Outcomes Research, Real World Evidence and Epidemiology

Savreet Bains Chawla is a health economics and outcomes researcher at Genmab, working within the Center for Outcomes Research, Real World Evidence & Epidemiology. She collaborates with research partners to design studies using real-world data and economic modeling to support health system decisions about the adoption of therapies. Her work focuses on treatment patterns, healthcare resource use, and patient outcomes in oncology, including hematologic malignancies and solid tumors. She welcomes collaborations with VA researchers to generate evidence that informs cancer care and supports better outcomes for Veterans.

Landon Shupe, PharmD

Associate Director, Health Evidence and Outcomes Liaison




Landon Shupe is a healthcare professional within oncology drug development across Medical Affairs, Market Access and Clinical Development. Currently serving as Associate Director, Health Evidence & Outcomes Liaison (HEOL) and VA Medical Affairs Lead at Genmab. Experience includes engaging population health decision-makers, leading Medical Advisory Boards, supporting lifecycle management and evidence generation, developing IST strategies, and partnering on key medical launch initiatives. Passionate about improving access to innovative medicines for Veterans and advancing evidence-based healthcare to ensure VA patients have timely access to meaningful new treatment option.



Ahead Together

GSK at a glance



Who we are

We are a focused biopharma company with a purpose to unite science, technology and talent to get ahead of disease together.

We aim to positively impact the health of more than 2.5 billion individuals by the end of the decade with ambitious plans for growth and continuing to make GSK a company where everyone can thrive.

What we do

We prevent and treat disease with specialty medicines, vaccines and general medicines.

In 2024:

£31.4bn

medicines and vaccine sales

71

medicines and vaccines in development

£6.4bn

R&D investment

13

positive phase III readouts

We focus on the science of the immune system and advanced technologies, investing in 4 core therapeutic areas (respiratory; immunology and inflammation; oncology; HIV; and infectious diseases) to impact health at scale.

We operate responsibly for all our stakeholders by prioritising Innovation, Performance and Trust.

Our portfolio:

Specialty Medicines



Our specialty medicines prevent and treat diseases, from HIV, cancer and asthma to immune-inflammation diseases like lupus.

Vaccines

Our broad vaccines portfolio targets infectious diseases at every stage of life.

General Medicines

From antibiotics to inhaled medicines for asthma and COPD, we have a broad portfolio of general medicine products, many of them leaders in their class, making life better for millions of people worldwide.



Our priorities

Innovation

We develop and launch new medicines and vaccines where they are needed, with better, faster and smarter R&D.
In 2024:

19

pipeline assets
in phase III/ registration

12

new collaborations
and acquisitions

Everyone at GSK is focused on our three long-term priorities:

Performance

Driven by our innovation, we have delivered consistent sales and profit growth and improved our long-term outlooks.

£ 31.4bn

medicines and vaccine sales

2.1bn

packs of medicines and
vaccine doses delivered

Trust

We focus on issues that matter most to our business, our stakeholders, and society, and where we can have the greatest impact.

2nd

in the Access to Medicine Index

91%

of our Responsible Business
Performance Rating metrics
'met' or 'exceeded'

Our culture

We have almost 70,000 people in 75 countries worldwide and culture at GSK is something we all own.

We are ambitious for patients to deliver what matters better and faster.

We are accountable for impact with clear ownership and support to succeed.


We do the right thing with integrity and care because people count on us.

This powers our purpose, drives delivery of our strategy and helps make GSK a place where people can thrive.

These are the foundations for how, together, we'll deliver more for our patients, shareholders and GSK people.

Why we do it

We aim to get ahead of disease together – to positively impact the health of 2.5 billion people by the end of the decade.



Heather F. Crouch, PHARMD, HECON-C



GSK Field Medical Account Lead

Dr. Crouch graduated Cum Laude from the MCV/VCU School of Pharmacy in Richmond, VA and has been an industry practice leader for over 25 years. With a wealth of therapeutic area experience across the GSK portfolio and pipeline, she is currently a GSK Field Medical Account Lead in a population health and market access medical role focused on the Federal customer segment. Her expertise ranges from vaccines and infectious disease to immunotherapeutics and oncology, as

well as certification in Health Economics. Dr. Crouch has spoken both regionally and nationally on a wide range of topics, including a presentation on Capitol Hill regarding the public health impact of immunizations. Her interests outside of work include cooking, gardening and trying to keep up with her husband and teenaged daughter.

Innovating with purpose to lead where medicine is going

At J&J Innovative Medicine, we aspire to develop breakthrough treatments to transform the future of health, discovering new pathways and modalities to be in front of diseases and find cures. Inspired by patients, we apply rigorous science with compassion to confidently address the serious health problems of today and develop the potential medicines of tomorrow.



\$54.8B+

In 2023 sales¹



#2

Pharma
company
worldwide ²



180M+

Patients
treated
globally with
one of our
medicines in
2022*



\$12B

2023 R&D
Investment³



~125%

more spent
on R&D than
sales and
marketing in
2023

Adjust as needed according to local market regulations.

Delivering 23 new medicines in the last decade and aiming to deliver up to 20 novel therapies and 50 product expansions by 2030.

Setting a new pace for discovery and delivery of transformational treatments by combining artificial intelligence, machine learning, real-world evidence and advanced computing with scientific expertise.

Above market Q2 2024 results driven by double-digit growth across 10 brands: DARZALEX®, TREMFYA®, ERLEADA®, EDURANT®, OPSUMIT®, SPRAVATO®, CARVYKTI®, RYBREVAANT®, TECVAYLI® and TALVEY®.

Boldly pursuing the best partners in the global innovation ecosystem to advance scientific breakthroughs and solutions to help patients.

¹ https://www.investor.jnj.com/files/doc_financials/2023/q4/Earnings-Infographic-4Q2023.pdf

² EvaluatePharma, September 2023

³ https://www.investor.jnj.com/files/doc_financials/2023/q4/form-10-k-2023-final.pdf

*Patients treated represents the estimated number of people globally who were treated with a Janssen medicine in 2022, including patients reached through our VERMOX (mebendazole) donation program. This total excludes people vaccinated with our Janssen COVID-19 vaccine, which is reported separately. We estimated the number of patients treated by converting quantities of Janssen medicines into courses of therapy or total patient days of therapy per year and then converting those into numbers of people based on average utilization per patient. Patients taking multiple Janssen products may be counted as multiple patients in the total. Methodologies may vary by product type given the nature of the product and available data. Our estimated number of patients treated may be revised over time as we gain new information on patient usage or experience restatements in underlying data sources or changes in product portfolios.

Focused in areas where patient need is high, and our expertise is deep



Oncology

We are a team of innovators driven by our vision to **eliminate cancer**. We work diligently to get in front of cancer, and we will never settle until the disease is behind everyone.

With more than 30 years of delivering transformational innovations in oncology, our commitment to pioneer new frontiers and therapies for patients has never been stronger as we strive to redefine treatment paradigms in hematologic malignancies and solid tumors.



Immunology

Inspired by the promise of helping patients reclaim their lives, we action our distinct **immune pathway strategy** to deliver transformational and accessible therapies for patients with conditions in rheumatology, immunodermatology, gastroenterology, maternal-fetal immunology and rare autoantibody diseases.

Building upon our legacy of more 25 years, we are ushering in the next wave of immunology innovation.



Neuroscience

We are driven by our vision of leading the **precision neuroscience revolution** to reduce the burden and disability caused by serious nervous system disorders.

For more than 60 years, our goal has been to deliver breakthrough, outcome-improving solutions in areas of critical unmet need for people with neuropsychiatric, neurodegenerative and autoantibody-driven diseases.

Additional areas of interest



Cardiopulmonary

We have an unrelenting vision to ease the tremendous global burden of **cardiovascular disease**. While significant progress has been made in cardiovascular treatments over the past two decades, millions of patients remain untreated or undertreated because existing treatments present a risk of bleeding that can outweigh cardiovascular benefits.

We continue to build on our effort to transform **pulmonary arterial hypertension (PAH)** from a deadly disease into a manageable condition to help patients live better everyday lives. Our vision is to transform PAH, so patients can live a normal life.



Specialty Ophthalmology

We aim to achieve extraordinary discoveries, including gene therapy innovations. We won't stop striving until we **restore and preserve vision** for those living with retinal diseases.



Learn more at janssen.com/johnson-johnson-innovative-medicine

Keith Ware

Strategic Account Lead



As a Strategic Account Lead with a focus on Diversity at Janssen, Keith is focused on driving the strategy to increase Diversity, Equity, and Inclusion in our Oncology clinical trials. Keith's work in the industry spans over 15 years across patient and site engagement, as well as operational functions. Keith takes particular pride in having performed patient engagement at an investigative site, CRO and Sponsor. And believes this experience helps inform his holistic strategies and approach. Keith holds a BA from Ursinus College and a MS from Thomas Edison State University.

Tiffany Daugherty

Head of Military & Veterans Affairs and Specialty Strategies



Tiffany Daugherty is the Head of Military & Veterans Affairs at Johnson & Johnson, spearheading the company's holistic strategy and programming to support service members, veterans and military families.

Prior to joining Johnson & Johnson, Tiffany led Military & Veterans Outreach for Barclays, implementing successful hiring and retention strategies for veterans and military spouses. At First Data, her team received multiple national awards, including being ranked #1 on Military Times' "Best for Vets: Employers" list for three consecutive years. Under her leadership, Johnson & Johnson has achieved a #2 ranking on that same list.

Tiffany serves on the Board of Directors for Wounded Warrior Project and as Co-Chair of the Hiring Our Heroes – U.S. Chamber of Commerce Veteran Employment Advisory Council. She has been a vice chair of the NYC Veterans Advisory Board and was appointed by the Secretary of the VA to the Advisory Board on Women Veterans. An alumnus of the George W. Bush Institute's Stand-To Veteran Leadership Program, Tiffany holds a bachelor's degree from Austin Peay State University and a Master of Arts in Rehabilitation Counseling from Assumption College. She is a proud U.S. Army veteran.



At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines, as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us.

 \$14.5 Billion 2026 Revenues (as of May 5, 2026)	 36 Manufacturing sites worldwide	 ~200 Countries and territories where we sell our products	 96 Projects in our pipeline (as of May 5, 2026)
 ~75,000 Employees globally	 4 Products with sales greater than \$1B in 2026 (as of May 5, 2026)	CEO: Albert Bourla Global Headquarters: 66 Hudson Yards New York, NY 10001 (USA)	Web Site Address: https://www.pfizer.com Stock Exchange Listing: New York Stock Exchange (PFE)

Marc Miller

U.S. Director, Federal Healthcare Solutions Lead | Oncology



Marc Miller serves as the U.S. Director of Federal Healthcare Solutions Lead at Pfizer Oncology. Marc's mission involves partnering with national executives within the Department of Veterans Affairs and Department of Defense to advance national healthcare quality initiatives.

While in the military, Marc served as a U.S. Army Combat Medic in an Infantry Reconnaissance Unit. He also worked at Georgetown University's Lombardi Cancer Research Center conducting studies in Bone Marrow Transplant and Breast Cancer research. After transitioning to industry, Marc has worked in a wide variety of functional roles, focusing on cancers of the prostate, lung, bladder, and colon. With over 30 years of oncology experience, Marc is passionate about leveraging technology to accelerate innovation in healthcare systems and drive guideline-concordant care for active service members and veterans.

Siemens Healthineers



At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, and improving patient experience, all enabled by digitalizing healthcare.

An estimated five million patients globally everyday benefit from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics and molecular medicine, as well as digital health and enterprise services.

We are a leading medical technology company with over 120 years of experience and 18,500 patents globally. With about 50,000 dedicated colleagues in over 70 countries, we will continue to innovate and shape the future of healthcare.



Siemens Healthineers is committed to those who serve and have served in the United States Armed Forces. We are proud to support the paramount work of the U.S. Department of Veteran Affairs, Department of Defense, National Institutes of Health, Indian Health Service, Center for Disease Control and Prevention and Federal Bureau of Prisons.

 [Learn more](#)



Our portfolio

We are at the center of clinical decision making across the full healthcare spectrum.



Imaging

We are a market leader in diagnostic imaging with our systems for computed tomography, magnetic resonance imaging, molecular imaging, x-ray, ultrasound, and imaging IT.



Diagnostics

We bring clinical and workflow excellence to laboratories of any size with our testing systems, automation, and IT. With our point-of-care testing systems, we deliver lab-accurate, actionable, and timely results on the spot.



Advanced Therapies

We empower innovative therapy concepts and minimally invasive procedures with our angiography systems, mobile C-arms and hybrid ORs for image-guided therapy.



Services

With our customer services, we want to make sure systems are running properly and staff are trained. Our enterprise and digital services help providers to maximize opportunities and minimize risks in a transforming healthcare industry.

Globally, we are...

Market leader in majority of businesses

€14.5bn revenue¹

>70 countries with direct presence

~53,000 highly skilled employees

18,500+ IPRs, thereof 13,500 granted patents

~240,000 patient touch points every hour

Access to care for **>1.4bn people** in developing countries

>70% of critical clinical decisions are influenced by the type of technology we provide²

>90% of global top 100 providers partner with us

~600,000 installed base



¹Revenue FY 2019

²AdvaMed/DC, "A Policy Primer on Diagnostics", June 2011, p. 3

Our Value Promises



Expanding precision medicine

Precise diagnosis to foster individualized prevention and therapy.



Transforming care delivery

Accessible & highly efficient healthcare delivery leveraging established and new care models.



Improving patient experience

Improved patient experience across the continuum of care.



Digitalizing healthcare

Digital technologies to generate and utilize high-quality data from across the enterprise.

[Learn more](#)

Siemens Healthineers Headquarters

Siemens Healthcare GmbH
Henkestr. 127
91052 Erlangen, Germany
Phone: +49 9131 84-0
siemens-healthineers.com

USA

Siemens Medical Solutions USA, Inc.,
Healthcare
40 Liberty Boulevard
Malvern, PA 19355-9998, USA
Phone: +1-888-826-9702
siemens-healthineers.us

Phillip “Phil” J. Wellington, MBA

Vice President. Federal Accounts



Phil Wellington is the Vice President of Federal Accounts for Siemens Healthineers North America. He is chartered with strategically retaining, growing and evolving Healthineers business with the United States Federal Government Agencies. (Veterans Affairs, Department of Defense, Indian Health Service, National Institute of Health, Bureau of Prisons & Centers for Disease Control.)

He brings 20+ years of experience, in healthcare sales, healthcare supply chain, competitive strategy, corporate development, business building and executive leadership. Prior to joining Siemens Healthineers in 2019, he served as Vice President of Supply Chain Services at Premier Healthcare Alliance, a leading healthcare improvement company. At Premier, where he spent seven years, he was responsible for providing leadership in building their direct sourcing business, designing & leading the digital transformation of their alternate site business and their supply chain operations.

Preceding his time at Premier, Phil spent a decade at the pre-imminent federal

government consulting firm, Booz Allen Hamilton. At Booz Allen, Wellington worked on many strategic and corporate development projects. Early in his career, he spent time in the investment banking division of Prudential Securities.

Phil is active with The National Association of Corporate Directors (NACD), at both the national level and with the Charlotte Chapter. He is presently on the Boards of: Roots & Wings, a New York based charity dedicated to help people lift themselves out of poverty and Charlotte Soccer Academy Palmetto Football Club.

Wellington holds a Master's in Business Administration from The University of Florida, where he concentrated on Competitive Strategy, Finance and Security Analysis. He earned a Bachelor of Science in Biology from Georgetown University and honored in the Georgetown Athletic Hall of Fame. He resides with his wife and three children in Charlotte, North Carolina.

Smith+Nephew

Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. Alongside our customers we will not settle until we have solved the challenges of preventing and healing wounds, because they hold back too many lives.

Stuart D. Tyner, PhD

Contractor Supporting SN Military and Federal Health



Colonel (Retired) Stuart Tyner, Ph.D., is a Consultant supporting the Smith+Nephew Military and Federal Health Team. In this role he informs, coordinates, and develops enterprise R&D and clinical evidence efforts to partner with the Federal Health system. Dr Tyner is a scientist and leader in the field of infectious diseases research and military medicine.

Throughout his 22 year military career, Dr. Tyner served in various leadership positions, including Director of the \$750 million Defense Health Agency Infectious Diseases Portfolio and Director of the Military Infectious Diseases Research Program. He also served as Chief Science Officer at the US Army Institute of Surgical Research and the Chief of Staff at the Walter Reed Army Institute of Research.

In culmination of his service, Dr. Tyner was appointed as the lead policy advisor to the U.S. Army Surgeon General in microbiology. Dr. Tyner previously served as the Dept. of Defense's Ex Officio Member of the NIAID Steering Committee and holds an active faculty appointment at the Uniformed Services University of Health Sciences.

Dr. Tyner has two undergraduate degrees from the University of Notre Dame and a Ph.D. in Cell and Molecular Biology from Baylor College of Medicine. He was a National Cancer Institute Fellow at the National Institutes of Health and completed a Master's in Strategic Studies at the US Army Senior Service College (Army War College).



Takeda is a patient-focused, values-based, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future to people worldwide. Our passion and pursuit of potentially life-changing treatments for patients are deeply rooted in over 240 years of distinguished history in Japan.

Sean Cunningham

Senior Director – Study Site Engagement



Sean Cunningham is a Senior Director on Takeda's Study Site Engagement team, where he leads U.S. efforts to build and strengthen sponsor relationships that accelerate Takeda's portfolio and support an excellent clinical trial experience for study sites.

With more than 28 years of clinical operations experience, Sean has supported trials across Oncology, Infectious Diseases, Metabolism, Gastrointestinal/Inflammatory, Dermatology, Cardiovascular, Neuro/Psych, and Rheumatoid Arthritis.

Sean holds an MBA with an emphasis in Healthcare Marketing and Strategy from the Olin Business School at Washington University in St. Louis, and a BA from the University of Colorado Boulder.

Jen Ryan

Senior Study Start-Up Manager



Jen Ryan is a Senior Study Start-Up Manager with Takeda Pharmaceuticals. She has over 13 years of clinical experience in a variety of therapeutic areas including Oncology, Endocrine/Metabolic, Cardiovascular, Dermatology, Infections Disease, Neuro and Transplant. Jen has led and supported global startup activities at an investigative site, CRO and sponsor. This range of experience provides a unique understanding and respect for the challenges teams face in the early start-up phase of conducting clinical trials. Jen resides in Ohio with her husband and three children.



NPC Representatives



LOWCOUNTRY CENTER FOR VETERANS RESEARCH

Brittany Baber

Executive Director

Brittany serves as the Executive Director of LCVR, bringing over 20 years of experience in clinical research, organizational leadership, and program development. She holds a bachelor's degree in Organizational Leadership and Management from the College of Charleston, which supports her work in advancing impactful research initiatives that improve the health and well-being of veterans in the Lowcountry.

With a passion for driving innovation, Brittany has played a pivotal role in fostering collaborations with the Ralph H. Johnson VA Health Care System and other key stakeholders. Under her leadership, LCVR has expanded its clinical research capacity, serving as a hub for groundbreaking studies that address the unique health needs of veterans.



VETERANS MEDICAL RESEARCH FOUNDATION

Jean Freiser

Contracts and Grants Pre-Award & Business Development Director

Jean Freiser serves as Contracts and Grants Pre-Award & Business Development Director at the Veterans Medical Research Foundation. She joined Veterans Medical Research Foundation (VMRF) in July 2016. She also served in a consultancy role at VMRF previously.

In her capacity as Director, she provides management and direction for all pre-award grants and contracts activities, as well as clinical trial development. Jean is responsible for the research business development opportunities consistent with VMRF's priorities, mission and annual Strategic Goals. Jean is an instrumental member of the Leadership Team. She is proficient in the development and successful submission of grants, contracts and industry sponsored research agreements. In addition, she develops strategies to identify and obtain Federal funding for the VMRF research programs. Jean was instrumental in the development of a VMRF Pilot Project Research Award Program.

Jean is an accomplished research administrator with a broad knowledge of pre and post award grant and contract management for Federal, State and private foundations. She has proven ability to identify funding opportunities and has a comprehensive knowledge of governmental and other research funding agencies.

Jean is a Certified Research Administrator and is an active member of the Society for Research Administrators International (SRA), the Associated Independent Research Institutes (AIRI), and the National Association of Veterans' Research and Education Foundation (NAVREF).



BAY PINES FOUNDATION

Caitlin Mahaney

Executive Director

Caitlin Mahaney is the Executive Director of Bay Pines Foundation, a role she has held since 2020. Caitlin's journey at Bay Pines Foundation began in 2014 as a Clinical Research Coordinator — giving her firsthand experience in the day-to-day realities of trial management, budget execution, and sponsor relationships that she now oversees from the executive level. That ground-up perspective shapes her practical, no-nonsense approach to sponsored project administration. With more than a decade of experience in clinical research, Caitlin brings a combination of hands-on scientific expertise and organizational leadership that informs her results-driven approach to clinical trial administration.



NORTHERN CALIFORNIA INSTITUTE FOR
RESEARCH AND EDUCATION

Newton Ong

Manager, Compliance and Contracts

Newton Ong has been with the Northern California Institute for Research and Education (NCIRE) for over 25 years and brings extensive research experience. He has been promoted into various positions including: Clinical Trials Specialist, Clinical Research Center Administrator, Contracts and Grants Manager, and his current position as NCIRE's Compliance and Contracts Manager which he co-manages the Contracts and Grants Department. Newton received his Bachelor of Science, Business Management from San Francisco State University. His areas of professional expertise include business administration, research administration, compliance, contract negotiations and management (CTA and CRADA), clinical trial site administration and finances, and assists with facilitating research with the SFVA Research and Development Department. He is also Clinical Research Contract Professional (CRCP) certified by MAGI.



DORN RESEARCH INSTITUTE

Chris Wood, PhD

Executive Director

Chris received his Ph.D. in Pharmacology from Wayne State University and received his postdoctoral training at the University of Pennsylvania. For 15 years he worked in various disciplines of biomedical research, leading studies and communicating scientific data clearly and concisely to fellow scientists, the general public and medical communities. He also spent time working as a fundraiser for the University of South Carolina, where he was a liaison between the University and its community partners. In 2020 Chris started as the Executive Director of the Dorn Research Institute in Columbia SC and has utilized his research background, leadership skills and relationship building to grow the program. Both of his grandfathers were in the military, and he is honored to serve our Nation's Veterans through his work at the Dorn Research Institute.